GettyNew results presented today at the American Society of Clinical Oncology annual Meeting in Chicago have shown that the addition of a drug called a cyclin inhibitor significantly increases the chance of survival for younger women with a particular type of aggressive breast cancer. Although advanced breast cancer is less common in younger women than older woman, it appears to be becoming more common. "Increased survival is important, but the unfortunate reality in metastatic breast cancer, is that its unusual to 'cure’ women with advanced breast cancer with any of our current therapies. But, the history of cancer treatment has generally been modest, incremental steps over time in contrast to blockbuster breakthroughs," said Lichtenfeld. Palbociclib has already been tested in a similar trial in younger women with advanced breast cancer, but didn't show the same increases in overall survival as the recent research with ribociclib.

Source: Forbes June 01, 2019 15:09 UTC